UnitedHealthcare Chelation Coverage Update

Coverage Criteria for Chelation Therapy

Chelation for heavy metal toxicity and overload conditions

Covered when ALL of the following are met:

Established overload diagnosis: There is an accurate diagnosis of heavy metal overload (eg, iron, copper, lead, aluminum) supported by history and appropriate, specific testing and reference values.

Diagnostic workup must consider individual history, appropriate testing methods, and use of accurate and specific reference values.

Appropriate agent and monitoring: Chelation is selected based on the chelating agent, toxicity level, and other clinical indications, with appropriate monitoring for efficacy and adverse effects.

Use FDA‑approved chelating agents for their approved indications and monitor for known toxicities.

Not medically necessary / Unproven indications

Not medically necessary (unproven):

Mercury from dental amalgams: Chelation therapy for treating mercury 'toxicity' from dental amalgam fillings is unproven and not medically necessary.

High‑quality RCTs and reviews do not support harm from amalgams that would warrant chelation.

Non‑overload chronic progressive diseases: Chelation therapy for treating chronic, progressive diseases associated with non‑overload conditions (eg, cardiovascular disease, Alzheimer's disease, autism spectrum disorder, Parkinson's disease, cancer, diabetes, rheumatoid arthritis, and other listed conditions) is unproven and not medically necessary due to insufficient evidence of efficacy.

Systematic reviews and health technology assessments identify weak, conflicting, or insufficient evidence for these indications.

Indications considered medically necessary

Covered when ALL of the following are met

Documented metal intoxication: Validated diagnostic testing in appropriate biological samples confirms clinically significant metal poisoning (eg, lead poisoning, iron overload) consistent with accepted diagnostic reference ranges.as per diagnostic test reference ranges

Per AAFP and ACMT position statements: chelation is appropriate only for documented metal intoxication.

Not medically necessary / investigational indications

Not covered / investigational when ANY of the following apply

Autism Spectrum Disorder: Chelation therapy for ASD is not supported—Cochrane and other reviews report no clinical benefit and note serious adverse events (eg, hypocalcemia, renal impairment, reported deaths).N/A

Risks currently outweigh benefits; further trials require clear causal link and safety assurances.

Cardiovascular disease / ASCVD / stable ischemic heart disease: EDTA‑based chelation for CAD/ASCVD or to prevent myocardial infarction or death is not supported by sufficient evidence; systematic reviews and trials show inconsistent benefit and major guidelines do not recommend routine use.N/A

TACT and later trials/systematic reviews are hypothesis‑generating only and insufficient for routine coverage.

Parkinson's disease: Iron chelation (eg, deferiprone) in Parkinson's disease is investigational; small trials show biochemical or imaging changes but no conclusive patient‑centered outcome benefit.

Coverage stance: Overload/toxicity versus non-overload indications

Covered when ALL of the following are met

Proven/medically necessary indications: Chelation therapy using FDA‑approved chelating agents for metal poisoning or iron overload (eg, iron, copper, lead, aluminum) is considered proven and medically necessary.

Policy revision explicitly states these overload/toxicity indications are proven and medically necessary; use per FDA‑approved indications and referenced compendia.

Non‑overload/experimental indications: Chelation used for non‑overload indications (eg, attempting to improve angina/exercise tolerance in stable ischemic heart disease or to treat core symptoms of autism) is not supported by referenced guidelines and systematic reviews.

Referenced guideline sources include AHA, Canadian Cardiovascular Society, NICE, and major toxicology/medical societies.

Chelation therapy is not supported for a broad set of non-overload conditions. Well-designed, peer-reviewed studies do not demonstrate safety or efficacy of chelation for chronic, progressive diseases such as cardiovascular disease, Alzheimer’s disease, autism spectrum disorder, Parkinson’s disease, diabetes, cancer, rheumatoid arthritis, and multiple other conditions listed in the evidence review. Small, methodologically limited studies, heterogeneous regimens, and inconsistent outcomes mean these indications are considered not medically necessary (unproven).

Requests for chelation for non-overload indications may be denied unless there is documentation of a validated diagnosis of metal intoxication. The policy requires an accurate diagnostic workup using appropriate testing and reference values before chelation is considered medically necessary.

When authorizing chelation for suspected metal intoxication, the member’s record must contain validated diagnostic testing performed on appropriate biological samples that confirm clinically significant metal poisoning. Clinical practice guidance from major societies specifies chelation only for documented intoxication diagnosed by validated tests.

Documentation should include relevant history, specific laboratory or imaging results with reference ranges supporting the diagnosis, the chelating agent proposed, and a monitoring plan for efficacy and potential adverse effects. Prior authorization processes require this evidence to justify treatment for overload/toxicity indications.

Examples of non-covered uses include chelation to improve angina or exercise tolerance in stable ischemic heart disease. Multiple guideline bodies (ACP, Canadian Cardiovascular Society, AHA) advise against using chelation for symptom relief or to reduce cardiovascular risk in stable IHD and do not endorse routine EDTA chelation for prevention of MI or death.

Chelation to treat core symptoms of autism is not supported. A Cochrane review and randomized trials found no evidence that pharmaceutical chelation improves ASD symptoms and reported serious adverse events (eg, hypocalcemia, renal impairment), so such use is considered not medically necessary.

Chelation for alleged mercury toxicity from dental amalgam fillings is not an accepted indication; systematic reviews and regulatory statements indicate amalgam fillings have not been shown to cause harm requiring chelation except in rare allergic cases.

Chelation for mercury attributed to dental amalgam fillings is considered not medically necessary. The evidence does not show that routine exposure from dental amalgams causes clinically significant mercury toxicity that requires chelation, except in rare cases such as documented allergy.

FDA communications note specific high-risk groups for whom avoiding mercury-containing amalgams may be appropriate, but the FDA also states that FDA-approved chelating agents are indicated for defined uses such as lead poisoning and iron overload—not for treating autism or other non-overload conditions. Accordingly, chelation for dental amalgam-related concerns is not covered absent documented intoxication.

Routine use of EDTA-based chelation to prevent or treat cardiovascular disease is not supported by the totality of evidence. Systematic reviews and randomized trials, including the pivotal TACT study and subsequent analyses, have not established consistent benefits on mortality or major cardiovascular outcomes to justify routine clinical use for ASCVD.

Major clinical guidelines explicitly state that EDTA is not approved by the FDA for preventing or treating cardiovascular disease and recommend against using chelation to improve symptoms or reduce cardiovascular risk in patients with stable ischemic heart disease.

Non-overload conditions (for example, stable ischemic heart disease or neurodevelopmental disorders) lack high-quality evidence of clinical benefit from chelation and carry potential for serious harms. Professional societies and systematic reviews conclude chelation should be restricted to documented metal intoxication; use for cardiac indications or to treat core symptoms of autism remains investigational and is generally not recommended.

When chelation is considered outside of proven overload/toxicity indications, it should only occur in the context of well‑controlled clinical trials with appropriate safety monitoring; routine clinical use for these non-overload cardiac or neurologic indications is not supported.

Agents and Regimens Referenced

Regimen / Agent	Indication / Notes	Coverage Status
Deferoxamine (parenteral)	Used in transfusion‑dependent iron‑overload (e.g., thalassemia, sickle cell disease); parenteral infusion over prolonged periods; associated adherence challenges due to infusion burden.	Covered
Deferiprone (oral)	Oral iron chelator evaluated in randomized trials and noninferiority studies (DFP shown noninferior to DFX for LIC and cardiac T2* in some trials); adverse events include gastrointestinal symptoms, neutropenia, agranulocytosis.	Covered
Deferasirox (oral)	Oral iron chelator with formulations as tablets/granules; compared with DFP in randomized trials (noninferiority demonstrated in some studies); associated with hepatic, gastrointestinal, and renal toxicities.	Covered
Combination regimens (DFP + DFX; DFX/DFP ± DFO)	Combination dual‑chelation strategies have been reported to reduce liver iron concentration (LIC) and improve cardiac MRI T2* with generally acceptable adherence and tolerability in small studies and systematic reviews; comparative studies showed no consistent difference in post‑treatment ferritin between combination and monotherapy in reviewed studies.	Covered

Billing and Coding

Referenced HCPCS/J-codesHCPCS

J0470	Injection, dimercaprol, per 100 mg.
J0895	Injection, deferoxamine mesylate, 500 mg.
J3490	Unclassified drugs.
J3520	Edetate disodium, per 150 mg.
J8499	Prescription oral, nonchemotherapeutic, NOS drug.

HCPCS Per-diemHCPCS

S9355

Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

Clinical endpoints referenced in studies

Serum ferritinUsed as a primary biochemical endpoint in multiple iron‑chelation studies to track body iron stores and response to therapy (reduced with effective chelation).

Liver iron concentration (LIC)Measured by MRI (R2*/R2) in trials as a direct measure of hepatic iron burden and a key efficacy endpoint (significant reductions reported).

Cardiac MRI T2*Cardiac T2* MRI used to assess myocardial iron deposition; increases in T2* indicate reduced cardiac iron and were reported after effective regimens.

Overall survival (OS)Reported as a primary or major outcome in systematic reviews and MDS/ICT trials to assess mortality benefit associated with iron chelation therapy.

Event‑free survival (EFS)Used in randomized trials (eg, DFX vs placebo in lower‑risk MDS) as a composite patient‑centered endpoint (time to nonfatal event or death).

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for chelation therapy when used to treat documented metal intoxication or overload. Verify member plan benefits and obtain prior authorization per UnitedHealthcare Ohio processes before initiating therapy.

PA required for documented metal intoxication
Verify plan benefits and obtain prior authorization; use InterQual where applicable
Follow UnitedHealthcare Ohio prior auth processes

Documentation Required

Documentation Required for Overload Diagnosis

Documentation must demonstrate a diagnosis of metal overload/intoxication based on a comprehensive diagnostic workup. This should include relevant clinical history, exposure assessment, and objective testing performed with validated methods and appropriate biological samples.

Definitions

Heavy metal overload / toxicity — definition and diagnostic requirements

Clinical state definitionA clinical state in which accumulation of metals (eg, iron, copper, lead, aluminum) has been accurately diagnosed by history and appropriate, specific testing with reference values, and for which chelation is indicated.

Metals listedIron, copper, lead, aluminum.

Diagnostic requirementsDiagnosis must be supported by validated testing methods in appropriate biological samples and documented reference values prior to chelation.

Regulatory noteUse of FDA‑approved chelating agents is limited to FDA‑approved indications for metal poisoning or iron overload as referenced in drug compendia.

Non‑overload condition — definition

Evidence summary

Informational Line of Therapy Notes

Informational — Line of therapy top-level node

Informational: Iron chelation therapy is considered for patients with iron overload from chronic transfusions (eg, lower‑risk myelodysplastic syndromes, transfusion‑dependent hemoglobinopathies); agents referenced include deferoxamine (parenteral), deferiprone (oral), and deferasirox (oral).

Clinical trials and systematic reviews document effects on serum ferritin, liver iron concentration, cardiac T2*, survival, and other endpoints; benefits must be balanced against toxicity and treatment complexity.

Background and Rationale

Chelation therapy is an established medical treatment that uses agents to bind and enhance excretion of specific heavy metals. It is considered proven and medically necessary for diagnosed heavy metal overload or poisoning (for example, iron, copper, lead, aluminum) when diagnosis is confirmed by appropriate testing and reference values.

Evidence supports use of specific chelating agents for defined overload syndromes (for example, parenteral deferoxamine and oral agents such as deferiprone or deferasirox for iron overload) with monitoring for efficacy and adverse effects. FDA-approved indications and reputable drug compendia should guide agent selection and dosing.

Policy Revision History

2025-08-01revisionLatest

Replaced prior language to explicitly state chelation for heavy metal toxicity and overload conditions (eg, iron, copper, lead, aluminum) is proven and medically necessary; updated Clinical Evidence and References; archived previous policy version CSO16OH.B.

OpenPayer

Chelation Therapy (for Ohio Only)